Hypoglycemic activity of MTP-1403 (2-amino-7,8-dihydro-4-piperazinyl-6H-thiopyrano 3,2-d pyrimidine), a new hypoglycemic agent.

Abstract

2-Amino-7,8-dihydro-4-piperazinyl-6H-thiopyrano 3,2-d pyrimidine (MTP-1403) is a new oral hypoglycemic agent structurally different from any existing hypoglycemic drugs. MTP-1403 lowered fasting plasma level and dose-dependently improved glucose tolerance test without increasing insulin secretory response to glucose. MTP-1403 caused a decrease in fasting plasma glucose level in mild alloxan-induced diabetic rats but not in the rats suffering from ketosis. MTP-1403 markedly improved the oral glucose tolerance test in the genetically diabetic KK mice. These results suggest that hypoglycemic activity of MTP-1403 may be mechanically different from sulfonylureas and biguanides and beneficial to type II diabetics with hyperinsulinemia and insulin resistance.

• Authors: Y Kunoh, A Iguchi, M Gotoh, T Nomura, M Shibata, N Sakamoto
• Journal: Archives internationales de pharmacodynamie et de therapie (Arch Int Pharmacodyn Ther) Vol. 280 Issue 2 Pg. 302-13 (Apr 1986) ISSN: 0003-9780 [Print] Belgium
• PMID: 3521517 (Publication Type: Journal Article)

Chemical References

• Blood Glucose
• Hypoglycemic Agents
• Insulin
• Pyrimidines
• Sulfhydryl Compounds
• MTP 1403

Topics

• Animals
• Blood Glucose (metabolism)
• Diabetes Mellitus, Experimental (blood)
• Glucose Tolerance Test
• Hypoglycemic Agents (pharmacology)
• Insulin (blood)
• Male
• Pyrimidines (pharmacology)
• Rats
• Rats, Inbred Strains
• Sulfhydryl Compounds (pharmacology)
• Time Factors